Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya

Table 4 Intermediate and cumulative systems effectiveness of delivery of IPTp-SP (any dose)

IPTp-SP arm (N = 342)^a	N	n	Intermediate process effectiveness, % (95% CI)	Cumulative delivery effectiveness %
DOT
1. 2nd or 3rd trimester^b	342	336	100
2. Given any SP^c	319	239	74.9 (54.8,88.0)	74.9
3. Given dose of 3 tablets	239	237	100	74.9
4. Took dose by DOT	237	179	75.5 (31.7,95.4)	56.5
With or without DOT
1. Given any SP	319	239	74.9 (54.8,88.0)	74.9
2. Given dose of 3 tablets^d	239	237	100	74.9
3a. Took dose by DOT	237	179	75.5 (31.7,95.4)	56.5
3b. SP not given by DOT	237	58	24.5 (4.6,68.3)	24.5
4. Has SP on exit	58	2	3.4 (0.2,38.0)	3.4
5. Knows how to take 3 tablets SP^e	2	1	100.0 (0,100)	3.4
6. Composite endpoint	336	180		53.6

^aAnalysis limited to participants who were not given any antimalarial for treatment and/or antiretroviral and for whom information on drugs received was available at exit
^b6 missing
^c17 missing
^d2 missing
^e1 missing

ISSN: 1475-2875